GlassScriptPhysician profile
Clinton C Turner
NPI 1659660314
$3,869.28
in general payments reported to CMS, 2019-2025
33 companies · $585 in 2025
The $585 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $824 · 2021: $506 · 2022: $457 · 2023: $525 · 2024: $644 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,753.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $857.21 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $498.26 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $497.74 | 2020-2024 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $345.71 | 2019-2025 | Evenity, Prolia, Prolia |
| Pfizer INC. | $297.16 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $156.51 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Exact Sciences Corporation | $140.21 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $137.54 | 2021-2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $102.52 | 2020-2024 | |
| Abbvie INC. | $102.07 | 2021-2025 | Vraylar |
| Phathom Pharmaceuticals, INC. | $85.02 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $76.94 | 2020-2022 | |
| Glaxosmithkline, LLC. | $69.51 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Allergan, INC. | $39.60 | 2019-2021 | |
| Gilead Sciences, INC. | $36.86 | 2021-2023 | Epclusa |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $36.32 | 2025 | |
| Biogen, INC. | $35.28 | 2024-2025 | Skyclarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.02 | 2020-2022 | |
| Dexcom, INC. | $32.96 | 2022-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.69 | 2020-2025 | Xifaxan |
| Sanofi Pasteur INC. | $30.92 | 2020-2023 | |
| Genentech USA, INC. | $27.65 | 2020-2021 | |
| Eisai INC. | $26.73 | 2020-2021 | |
| Antares Pharma, INC. | $23.63 | 2025 | Xyosted |
| Horizon Therapeutics Plc | $23.09 | 2022 | |
| Seqirus USA INC | $21.98 | 2025 | Fluad, Flucelvax |
| Philips North America LLC | $18.80 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $15.52 | 2025 | Zoryve |
| Astellas Pharma US INC | $15.48 | 2020 | |
| Abiomed | $14.87 | 2025 | |
| Ironwood Pharmaceuticals, INC | $13.34 | 2022 | |
| Idorsia Pharmaceuticals US INC | $12.58 | 2022 | |
| Currax Pharmaceuticals LLC | $12.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clinton Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.